Van Le is Global Head of R&D Intellectual Property for Cardiovascular, Renal & Metabolism (CRM) at Novartis, where she leads IP strategy across discovery through late-stage development. At Novartis, she and her team partner with research, clinical, and business teams to protect innovation, enable strategic collaborations, and provide IP support for M&A, licensing transactions, and divestments. In this capacity, she has the perspective of seeing the evolution of deals starting from early stages of engagement and deal negotiations to integration and support of assets after the deals, as well as termination in some cases.
Before joining Novartis, Van practiced at Jones Day as an associate, advising life sciences clients on patent prosecution, due diligence, freedom-to-operate, licensing, and portfolio strategy.
Van holds a Ph.D. in Molecular & Cell Biology from Cornell University, a J.D. from Fordham University School of Law, and a B.S. in Chemical Engineering from MIT. Bridging deep scientific training and legal expertise, she builds high-quality, globally aligned patent estates that support partnerships, market access, and patient impact.